Radioresistant malignant myoepithelioma of the breast with high level of ataxia telangiectasia mutated protein.
Malignant myoepithelioma of the breast (MMB) is a rare and often aggressive disease with poor prognosis. Little is known regarding its optimal treatment and progression. We describe the clinical history of a woman following excision of a benign adenomyoepithelioma which recurred years later as a radioresistant malignant myoepithelioma with high levels of ataxia telangiectasia mutated protein and mutant p53 (Cys135Phe). MMB requires close follow-up and aggressive treatment. If adjuvant radiotherapy is adopted to improve local control, minimal postoperative delay and higher doses than for standard post-mastectomy radiation are recommended.
Fang
Z M
ZM
Department of Radiation Oncology, South Eastern Area Laboratory Service, St George Hospital, St George Clinical School, University of New South Wales, Kogarah, New South Wales, Australia.
Tse
R V
RV
Marjoniemi
V M
VM
Kozlov
S
S
Lavin
M F
MF
Chen
H
H
Kearsley
J H
JH
Graham
P H
PH
Clarke
R A
RA
D064007:Ataxia Telangiectasia Mutated Proteins; D001943:Breast Neoplasms / Q000378:metabolism* / Q000532:radiotherapy*; D018797:Cell Cycle Proteins / Q000032:analysis*; D004268:DNA-Binding Proteins / Q000032:analysis*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009208:Myoepithelioma / Q000532:radiotherapy*; D017346:Protein Serine-Threonine Kinases / Q000032:analysis*; D017211:Treatment Failure; D025521:Tumor Suppressor Proteins / Q000032:analysis*
D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins; D025521:Tumor Suppressor Proteins; C576324:ATM protein, human; D064007:Ataxia Telangiectasia Mutated Proteins; D017346:Protein Serine-Threonine Kinases